This paper presents the long-term results of treatment for children with acute lymphoblastic leukemia (ALL) as conducted by the Pediatric Oncology Group (POG) from 1986 to 1994. The data are presented using standard NCI/Rome risk criteria. The overall event-free survival (EFS) at 5 and 10 years were 70.9% and 67.3% for children with B-precursor ALL, 51.0% and 50.2% for patients with T cell ALL, and 22.4% and 20.9% for infants with ALL. Concomitant biologic studies found that in B-precursor ALL a DNA index (DI) of у1.16 and trisomies of both chromosomes 4 and 10 were good prognostic indicators for patients with B-precursor ALL. The traditional prognostic indicators (age and white count), DI and trisomies did not predict outcome in patients with T cell disease. Infants continued to do poorly overall despite more intensive therapy with rotating pairs of chemotherapy. We recommend continued reporting of study results using common risk criteria in order to facilitate comparisons both within and across study groups. Leukemia
Introduction
The past 40 years have seen a dramatic improvement in the cure rate of childhood acute lymphoblastic leukemia (ALL). Common elements in most successful protocols have included: three-or four-drug induction, a post-induction intensive phase of treatment, and central nervous system prophylaxis. Treatment intensity has been tailored to the risk of relapse for specific subgroups of patients. However, definitions of these risk groups have varied. This has made it difficult to compare the results of different treatment regimens.
Recently, nearly identical consensus criteria for risk classification were recommended at two separate meetings. 1, 2 Adoption of these definitions would facilitate both withingroup and between-group comparisons of treatment results.
A review of the studies done from 1986 to 1994 by the Pediatric Oncology Group (POG) is reported here. During this time period, POG conducted two randomized studies for the treatment of B-precursor ALL, one phase III study for T cell ALL and three infant ALL studies. Concurrent biology studies with centralized laboratory testing defined a risk-group approach to treatment using cytogenetic and flow cytometry results in addition to patient age and white blood cell count (WBC). In this paper we report the long-term results of these studies using consensus risk criteria. We also comment on some of the important biological lessons learned from these studies. 
Materials and methods

Patients
From 1986 to 1994, 3828 eligible children with newly diagnosed B-precursor ALL were enrolled on POG protocols. The ALinC 14 studies (protocol 8602) covered the time from 1986 to 1990 and the ALinC 15 (protocols 9005/9006) studies covered the time period from 1990 to 1994. [3] [4] [5] [6] [7] Patients eligible for these studies were 1.00-21.99 years of age. The diagnosis of non-T, non-B ALL was confirmed by negative Sudan Black B (or peroxidase) and negative esterase stains and surface marker studies showing B-lineage antigen expression. Patients with pre-B ALL had blasts expressing cytoplasmic immunoglobulin (cIg), but not surface immunoglobulin (sIg). Cytogenetic studies of the leukemic cells were performed by routine methods. Results were considered informative only if karyotype abnormalities were demonstrated. Flow cytometry was used to derive the DNA index (DI), which was used to estimate ploidy. POG reference laboratories performed the immunophenotyping, cytogenetic and DI studies for each patient who was registered on a treatment study. 8 From 1986 to 1992, 439 eligible patients with newly diagnosed T cell ALL were enrolled on POG protocols 8691 and 8704. 9 Eligibility requirements for these studies included 1.00-21.99 years of age, and T cell ALL confirmed by blast cell expression of at least two of the antigens CD7, CD5, and CD2 or expressing only CD7 in the absence of myeloid antigens. The patients could not have received any prior therapy except for emergent steroids or irradiation for respiratory distress. POG 8691 piloted the regimens that were used for 8704. The first 97 patients were enrolled on 8691. Once the initial data were reviewed, new patients were then enrolled on 8704, which was a randomized comparison.
From 1986 to 1993, 141 eligible infants with ALL were enrolled on three POG studies (protocols 8493, 8398 and 9107). 10, 11 Patients had to be Ͻ1.00 years of age with previously untreated ALL. Infants with T cell ALL and B cell ALL were not eligible. Flow cytometry and cytogenetics were performed according to the same classification studies.
Patients with mature B cell ALL (sIg positive and K or positive) were ineligible for all of the studies reported in this paper. The exception was the rare patient with B cell ALL and non-L 3 morphology; such patients were eligible for the Bprecursor protocols.
All studies were approved by the institutional review board for each participating center. Informed consent was obtained prior to registration and enrolment.
Treatment
Treatments are summarized in Table 1 . For ALinC 14, all patients received a three-drug induction therapy with vincris-2277 Table 1 Outline of treatment by each study tine, prednisone and L-asparaginase (ASP) prior to randomization. Patients were then randomized to consolidation with: A, every 3 weeks intermediate-dose methotrexate (IDMTX); B, A + weekly asparaginase; C, A + cytosine arabinoside (araC); D, every 12 weeks IDMTX + araC. [3] [4] [5] Patients with POG goodrisk (defined as age 1.0-10.99 years with presenting WBC count Ͻ10 000/l or age 3.0 to 5.99 years with a WBC of 10 000 to 99 999/l) ALL were randomized to all four regimens while patients with POG poor risk (age у11 years with any presenting WBC count; age 1-2.99 or 6-10.99 years with WBC 10 000 to 99 999/l; a presenting WBC Ͼ100 000/l at any age; liver or spleen below umbilicus; or extramedullary leukemia) were randomized to regimens B, C, and D. Patients with CNS disease (у5 WBC per l of CSF with blasts on cytospin) at diagnosis, or with Philadelphia chromosome-positive ALL were assigned non-randomly to regimen C. Patients with pre-B ALL (cIg+) were randomized to regimens B and C. CNS prophylaxis consisted of methotrexate, cytosine arabinoside, and hydrocortisone given intrathecally. Patients with CNS disease at diagnosis received cranial irradiation therapy.
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ALinC 15 included POG studies 9005 and 9006. Patients received either a three-(vincristine, prednisone, Lasparaginase) or four-drug (three drugs plus daunomycin) induction based on presenting age and WBC. Protocol 9005 for good risk ALL (see above) compared intensification with IDMTX plus intravenous 6-mercaptopurine (IVMP) (regimen A), repeated low-dose oral methotrexate plus IVMP (regimen B), and IDMTX alone (regimen C). 6, 7 In addition to the POG good-risk patients, patients with POG poor-risk ALL (without CNS disease) who had a DNA index у1.16 were also eligible for this study. Protocol 9006, for POG poor risk ALL, randomized intensification between: A,12 courses of IDMTX plus IVMP; and B, 12 rotating courses (IDMTX plus IVMP, VM-26 plus araC, IDMTX plus IVMP, vincristine/prednisone/ ASP/daunomycin/araC: repeat sequence ×3). 12 Patients with t(9;22) or t(1;19) were nonrandomly assigned to 9006 regimen A (regardless of risk grouping). CNS prophylaxis consisted of methotrexate, cytosine arabinoside and hydrocortisone given intrathecally. Patients with CNS disease at diagnosis received cranial irradiation.
POG 8704 studied the efficacy of adding intensive highdose ASP to an established maintenance therapy for T cell ALL in an attempt to improve disease-free survival. 9 These regimens had been piloted in POG 8691. Patients with a WBC Ͻ50 000 at diagnosis received intrathecal therapy alone for CNS prophylaxis. Patients with a presenting WBC у50 000 received whole brain irradiation, while those with CNS disease at diagnosis received craniospinal radiation.
Infants with ALL were enrolled on one of three protocols. POG 8493 (1984) (1985) (1986) (1987) (1988) (1989) ) evaluated a regimen involving combination chemotherapy with methotrexate/mercaptopurine, araC/vincristine/prednisone/cyclophosphamide, and VM-26/cytosine arabinoside. 10 POG 8398 (1986 10 POG 8398 ( -1990 ) was a pilot study using regimen B of POG 9006.
11 POG 9107 (1991-1993) tested intensive post-induction chemotherapy with high-dose araC/daunomycin, IVMP/MTX, VP-16/araC, vincristine/prednisone/cyclophosphamide/araC. During the 2nd year, the araC/daunomycin courses were omitted. CNS prophylaxis was triple intrathecal medications.
Statistical considerations
The major emphasis on the statistical analysis is descriptive. The primary goal is to describe the long-term event-free survival, over subsets of interest, for the cohort diagnosed in the 1986-1994 time interval. Secondarily, we also reviewed the randomized treatment comparisons and conducted era comparisons within the period where applicable. While standard statistical methodology was used, including logrank tests for comparisons, 13 Kaplan-Meier 14 estimates of event-free survival, with standard errors of Peto et al, 15 there are some unusual features, necessitated by the complex study designs and the fact that the stratification pre-dated the NCI Consensus Risk Groups. For treatments with significant 'holes', either overall or within a risk group, no honest overall EFS estimates were deemed feasible. Within NCI consensus risk groups, one cannot assume prognosis is uniform. Since ALinC 14 was a two-way, three-way, or four-way randomization according to its stratification and time of entry, estimates had to be adjusted to the natural weights. Similarly, ALinC 15 used two-way or three-way randomization, leading to stratification to the natural weights. We employed the Cox proportional hazards model 16 for all randomized treatment comparisons, restricted to concurrently randomized patients.
For CNS outcome, we employed the cumulative incidence method of Kalbfleisch and Prentice. 17 This method essentially presumes an individual who fails for a non-CNS reason, is an infinite survivor with respect to CNS. This is more extreme than the Kaplan-Meier, which simply censors the patient at the point of competing failure. It follows that the cumulative a N/year, average number of patients enrolled per year for the duration of the studies.
incidence curve paints a more optimistic picture of CNS outcome than does the Kaplan-Meier. When it comes to isolated CNS relapse, the cumulative incidence method is biased toward underestimation of the true rate, and should be treated with caution. An event that appears clinically as a 'simultaneous CNS/other site event' is forgiven forever (ie handled as a cure) under a cumulative incidence function, even though it is certainly plausible that the event could have been an isolated CNS relapse initially, but it spread to the other site (eg marrow) before it was clinically diagnosed. Despite this methodological problem, we are presenting both isolated and overall cumulative incidence of CNS events to be consistent with the companion papers of other groups. Using patient entries to 1 January 1994, the loss to followup rates at 5 years were 5% for B-precursor ALL, 2% for T-ALL and 5% for infant ALL. While the rates increased after 5 years, the follow-up was still adequate for estimation purposes. The assumption of uninformative censoring, may in fact lead to a bias in the direction of underestimating the failure rate after 5 years, especially in the older children. If one looks at the Tables, one notes that estimated failure rates between 5 and 10 years are low in all the major subgroups.
Results
During both eras (ALinC14 and 15), 3828 eligible patients (non-infants) with B-precursor ALL were enrolled on POG protocols. Induction complete remission (CR) rates were 98% for patients with standard risk ALL and 95% for patients with high-risk ALL. The event-free survival (EFS) at 5 years was 70.9%, at 8 years was 69.0% and at 10 years was 67.3% ( Figure 1, Table 4a ). Of the above, 2697 patients had NCI standard risk ALL with an EFS of 77.4% at 5 years and 74.2% at 10 years ( Figure 1 and Table 2 ). Of the remaining 1131 patients, 1127 had NCI high risk ALL with an EFS of 55.3% and 50.8% at 5 years and 10 years, respectively ( Figure 1 and Table 2 ). Four patients could not be categorized by NCI risk, due to missing data.
In POG 8602, 1354 patients were classified as standard prognosis and 576 patients were classified as high risk. As expected, the patients with standard risk ALL did better than those with high risk ALL with 5 and 8 year EFS of 78.0% and 76.0% vs 53.1% and 49.3%, respectively (Table 3) . Comparing ALinC 14 and ALinC 15, there was no significant difference in outcome for patients with standard risk ALL: 5 year EFS of 78.0% and 76.8%, respectively. Patients with high risk ALL did slightly better on ALinC 15 studies with a 5-year EFS of 57.5% vs 53.1% on the ALinC 14 studies (P = 0.062 by logrank test). Outcomes by presenting features are summarized for all patients in Table 4a , by NCI risk groups in Tables  4b and 4c , and by treatment era in Table 4d. 2279  Table 3 Era comparisons for EFS By logrank test, P value for B-precursor, stratified for risk group is P = 0.48.
Figure 1
Event-free survival curves for patients with NCI good risk ALL (solid black line), NCI poor risk ALL (gray line), and all patients (dotted line) treated on ALinC 14 and 15 (POG 8602, 90005, 9006).
Table 4a
Event-free survival for non-infant B-precursor ALL (SE 
Figure 2
Event-free survival curve for all patients with T cell ALL treated on POG 8691 and 8704.
Figure 3
Combined event-free survival curve for infants with ALL treated on POG 8493, 8398 and 9107.
In study 8602, there was no significant overall difference in any randomized question (Table 5 ). Outcomes by risk groups are shown in Table 6 . However in study 9005, intermediatedose methotrexate (with or without IVMP) was superior to oral methotrexate for intensification (Table 5 ). Outcomes for regimen A (common to study 9005 and 9006) are presented by risk group in Table 6 .
From 1986 to 1992, 439 eligible patients with T cell ALL were enrolled on the two consecutive protocols. The induction CR rate was 96%. The 439 patients had an EFS of 51% and 50.2% at 5 and 10 years respectively ( Figure 2 , Table 2 ). The EFS by demographics, presenting WBC, CNS status, NCI risk groups and whether or not they received ASP in consolidation is shown in Tables 4e and 5 . This study showed that the addition of ASP improved the EFS (61.1% at 5 years) vs the control group (41.8% at 5 years). After 1993, POG ran a series of small T cell pilots, not included in this paper.
The three infant studies, enrolled a total of 141 patients. The induction CR rate was 92%. EFS for the pooled infant studies was 22.4% and 20.9% at 5 and 10 years, respectively ( Figure 3 and Table 2 ). The EFS by demographics, presenting WBC, CNS status, and presence of t(4;11) are presented in Tables 3 and 4f . There was no significant outcome difference among the three protocols.
Table 4b
Event-free survival for non-infant B-precursor good prognosis ALL (SE In ALinC 14, the cumulative incidence of isolated CNS relapse for patients with standard risk ALL was 3.0% at 5 years, 3.2% at 8 years and 3.2% at 10 years (Table 7) . For the high-risk patients during this study period, the relapse rates were 6.2% at 5 years, 6.4% at 8 years and 6.4% at 10 years. For the ALinC 15 studies, the cumulative incidence for an isolated CNS relapse was 3.6% at 5 years and 3.7% at 8 years for patients with standard-risk ALL. For high-risk patients, 5-and 8-year incidences were both 7.3%. For the T cell ALL patients, those that received ASP had a cumulative incidence of isolated CNS relapse of 1.8% at 5, 8 and 10 years vs 3.1% at 5, 8 and 10 years for the control regimen. For the infants, the isolated CNS relapse rates were: 8493, 12.9% at 5, 8 and 10 years, 8398, 6.7% at 5 and 8 years, and 9107, 4.2% at 5 and 10 years. For all the above studies, the cumulative incidence for any CNS event was approximately 50% higher than the incidence of isolated CNS relapse ( Table 7) .
Discussion
For children with precursor-B ALL treated on POG regimens, the EFS was approximately 70%, similar to results published by other groups. The backbone of POG consolidation therapy has been intravenous methotrexate. Repetitive low-dose oral methotrexate was inferior to intermediate-dose intravenous methotrexate in POG 9005. 6 One possible explanation was the overuse of leucovorin in the oral methotrexate regimen. Using a different rescue regimen, repeated oral methotrexate has been used successfully for consolidation by the DallasFort Worth group. 18 A recently completed POG ALL study for standard risk is evaluating divided dose oral methotrexate for delayed intensification prior to maintenance.
A 6-h infusion of IVMP did not improve results obtained with IDMTX alone in POG 9005. 7 Although this might reflect inadequate dose or scheduling of MP, other groups have also failed to show an advantage for IVMP. 19 Goldie et al 19a postulated that use of rotating non-cross resistant agents would be the ideal way to treat acute leukemia. POG 9006 attempted to study this question. 12 There was inconclusive benefit to rotating pairs when compared to repeated IDMTX for consolidation. This could mean that the Goldie-Coldman hypothesis is incorrect. More likely, it reflects (at least in part) that the agents used shared some mechanisms of resistance and were not equally effective.
Patients with pre-B (cIg+) ALL often have blasts with the t (1;19) . Patients with t(1;19)-positive ALL did poorly in ALinC 14. 20 On that study, they received six courses of IDMTX plus ASP or araC. However, in the ALinC15 studies, 12 courses of IDMTX and i.v. mercaptopurine negated the poor prognostic significance of this translocation. Other groups have reported similarly good results with more intensive therapy. 21 Thus, it appears that the poorer outcome initially found with this translocation may be overcome by using more intensive therapy.
Patients with Philadelphia chromosome-positive ALL did poorly. 22 However, the patients with this chromosomal abnormality but otherwise good prognostic features (according to the NCI criteria) had an EFS of 67% at 5 years with chemoLeukemia therapy alone on regimen A of POG 9005/9006. Thus, there may be a role for chemotherapy in a selected group of Ph+ positive patients. However, in a recent collaborative project, matched sibling bone marrow transplant gave better EFS even in this lower risk group of patients with Ph+ ALL. 23 ALinC 14 evaluated ploidy as a predictor of treatment outcome. A DNA index (DI) of greater than 1.16 was an independently favorable prognostic factor. 24 In combination with the leukocyte count and age, the DI was used to direct treatment allocation in ALinC 15. Other groups have also confirmed the prognostic significance of a DNA index Ͼ1.16.
25,26
Trisomies of several individual chromosomes were also associated with a better outcome. In particular, trisomies of both chromosomes 4 and 10 identified a subgroup of patients with an extremely favorable EFS. 8 When considered together, trisomies of 4 and 10 appear to be a stronger prognostic indicator than a DI of у1.16 when using POG therapy. In the Non-randomized special groups in AlinC 14, CNS, PH+, and non-L3 B cell were non-randomly placed on arm C. In the arm B estimation, we assumed the results would have been identical on arm B. These patients represent 2.3% of the good prognosis patients, 12.0% of the poor prognosis patients or 5.3% of the total. POG ALinC 16 and 17 studies, combined trisomy of 4 and 10 is used to allocate subsequent treatment following induction therapy. CCG has reported that trisomy of either chromosome 10 or 17 or 18 predicts a better outcome. 27 We speculate that the presence of any three of these four trisomies (4, 10, 17, 18) will place the patient at a lower risk of relapse.
Work continues on classifying patients into risk groups. Surface antigen phenotypes can predict the TEL-AML1 translocation, the presence of a rearranged MLL gene and the presence of an E2A-PBX1 translocation. 28 The presence of the Ph+ chromosome abnormality cannot currently be predicted by surface phenotyping. The ability to predict the presence of these molecular abnormalities by surface phenotyping can be used to reduce the number of samples requiring molecular testing for diagnosis.
Males, infants, adolescents, and non-Caucasian races continue to do less well. 29, 30 However, the outcome gap between races though still present appears to be narrowing. The genetic (pharmacologic?) basis of this difference should be investigated.
POG has treated patients with T-ALL on separate protocols based on the assumption that they have distinct biochemical characteristics. However, this approach has not been entirely successful. Perhaps some of the inconsistent results between approaches are due to the lack of truly lineage-specific Leukemia chemotherapy. POG 8704 showed that intensive high-dosed asparaginase consolidation improved the outcome for patients with T cell leukemia and advanced stage lymphomas, whereas this approach was not as efficacious in B-precursor ALL. 9 The BFM group has shown that high-dose methotrexate improved the outcome for this subset of patients. 31 The difference in efficacy of chemotherapeutic agents in B-precursor and T cell ALL support treating these two groups on separate protocols even if therapy is not truly lineage-specific. Recently, 506U has shown strong lineage specificity for patients with T cell disease. 32 A randomized study incorporating 506U in patients with newly diagnosed T cell disease is planned.
Several of the clinical and laboratory prognostic features which are used for precursor-B ALL are much less predictive in T cell ALL. 33 These include age, WBC, NCI consensus risk group, hyperdiploidy, and the presence of translocations. Other methods for predicting outcome in these patients are needed.
Infants continued to do poorly on the three studies reported here. However, preliminary data from a POG pilot study showed encouraging results with a more intensive treatment regimen. 34 Both ALinC 14 and 15 used intrathecal chemotherapy alone as prophylaxis for CNS leukemia in order to minimize tox-icities associated with CNS irradiation. The patients received methotrexate, hydrocortisone and ara-C (triple intrathecal therapy) or methotrexate alone. Our data show isolated CNS relapse rates equivalent to other strategies for CNS prophylaxis. However, an increased rate of acute neurotoxicity was noted in some patients. 35 The majority of the acute neurotoxic events were seizures. Computed tomography or magnetic resonance imaging showed evidence consistent with leukoencephalopathy in 75% of symptomatic patients. We have postulated that the increased neurotoxicity is due to lack of leucovorin rescue at the time of administration of the intrathecal methotrexate during consolidation. This is being investigated in retrospective studies. Current POG studies administer leucovorin with each intrathecal treatment during consolidation.
Therapy based on antimetabolites has been effective for the majority of children with ALL treated on POG protocols. Current efforts are being focused on the biology of the disease. Minimal residual disease at the end of induction and the effect it will have on outcome is being studied in the current POG ALL studies. Defining the molecular biology of the diseases and continuing work with lineage-specific therapy will be important for further improvement in the EFS of children with ALL.
